Examples include testing for epidermal growth factor receptor (EGFR) to determine the use of erlotinib in advanced nonsmall cell lung cancer (NSCLC), and KRAS testing to determine the use of cetuximab in advanced colorectal cancer. This evidence concerns the gene KRAS and lung cancer.